AF
CYTK icon

Advisornet Financial’s Cytokinetics CYTK Stock Holding History

Advisornet Financial’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1K Sell
260
-2
-0.8% -$144 ﹤0.01% 1360
2026
Q1 		$17.3K Sell
262
-49
-16% -$3.11K ﹤0.01% 1381
2025
Q4 		$19.8K Buy
311
+59
+23% +$3.67K ﹤0.01% 1331
2025
Q3 		$13.8K Sell
252
-21
-8% -$865 ﹤0.01% 1421
2025
Q2 		$9.02K Buy
273
+250
+1,087% +$8.7K ﹤0.01% 1511
2025
Q1 		$924 Sell
23
-4
-15% -$184 ﹤0.01% 1895
2024
Q4 		$1.27K Buy
27
+6
+29% +$312 ﹤0.01% 1672
2024
Q3 		$1.11K Buy
+21
New +$1.17K ﹤0.01% 1913
2024
Q1 		– Sell
-3
Closed -$250 – 2154
2023
Q4 		$250 Hold
3
– – ﹤0.01% 2259
2023
Q3 		$88 Hold
3
– – ﹤0.01% 2221
2023
Q2 		$98 Buy
+3
New +$111 ﹤0.01% 2273

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisornet Financial's CYTK Position: Q2 2026 in Review

Advisornet Financial reduced its Cytokinetics (CYTK) stake by 0.76% in Q2 2026, selling an estimated $144 and leaving 260 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1360.

Advisornet Financial first reported a position in CYTK in Q2 2023 and has held it in 11 quarters since. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Advisornet Financial held 260 shares of Cytokinetics worth $22.1K as of Q2 2026.
  • Advisornet Financial sold 2 Cytokinetics shares in Q2 2026, an estimated $144.
  • Cytokinetics made up ﹤0.01% of Advisornet Financial's portfolio in Q2 2026, its #1360 holding.
  • Advisornet Financial first reported a position in Cytokinetics in Q2 2023 and has held it in 11 quarters since.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.